Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

2025 Year in Review: Non–Small Cell Lung Cancer

home / publications / supplement / 2025-year-in-review-non-small-cell-lung-cancer

Opdivo plus Yervoy | Image: Bristol Myers Squibb

CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC

January 17th 2026

At the 6-year mark, CheckMate 9LA reveals significant long-term survival benefits for metastatic non-small cell lung cancer patients using dual immunotherapy with nivolumab and ipilimumab. These data were featured in the 2025 Year in Review in Non-Small Cell Lung Cancer.

2025 Year in Review: Non-Small Cell Lung Cancer

2025 Year in Review: Non-Small Cell Lung Cancer

December 15th 2025

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2026 MJH Life Sciences
AJMC®
All rights reserved.